PHARMACY

Santarus brings patent litigation against Par Pharmaceuticals over Zegerid

BY Allison Cerra

SAN DIEGO Specialty pharmaceutical company Santarus has filed a lawsuit against Par Pharmaceutical for patent infringements, the company said Thursday.

The lawsuit, which was filed with the U.S. District Court in Delaware, is in response to Par’s intention to market a generic version of Santarus’ Zegerid capsules prior to the July 2016 expiration of its three patents. The University of Missouri, licensor of the patents, has been listed as a co-plaintiff.

Par Pharmaceuticals recently filed for the new drug application with the Food and Drug Administration. If approved, the company will be granted market exclusivity.

Santarus has initiated the lawsuit within the 45 days required to automatically bar the FDA from approving Par’s application for 30 months, or until a district court decision that is adverse to Santarus.

Santarus is a pharmaceutical company that focuses on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

GSK will supply over 30 million doses of flu vaccines to U.S. this season

BY Drew Buono

PHILADELPHIA The influenza virus vaccines Fluarix and FluLaval from GlaxoSmithKline will have a combined total of 30 million to 35 million doses supplied to the U.S. markets for the 2007-08 influenza season.

The vaccines will be delivered in phased approach for the rest of September and all of October with completion occurring at the end of October. “Providing an ample and steadily growing supply of flu vaccine has been a priority for GlaxoSmithKline since entering the U.S. market in 2004,” said David Pernock, senior vice president of GSK. “Over the years, GSK has significantly increased its influenza vaccine manufacturing capacity, and we have taken steps to improve the way this product is distributed to those who need it.”

Last year, the company sent about 25 million doses of the drugs for flu season.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

NACDS pledges to award at least $100,000 in scholarships

BY Drew Buono

ALEXANDRIA, Va. The National Association of Chain Drug Stores Foundation is pledging to award at least $100,000 this year in scholarships, and has begun accepting applications.

Last year, 40 students were awarded a scholarship, an increase of three from 2005, and this year it looks like the foundation wants to add award the scholarship of $2,000 to at least 50 students. Also, some select recipients will receive named scholarships in the amount of $2,500, in addition to the $2,000 scholarship.

Applicants must be at least in their second year of pharmacy school, as well as have experience and the desire to work in a chain community pharmacy.

“The NACDS Foundation is continuously committed to advancing the pharmacy industry for the good of the public. An important part of our industry is its future, and that is what these students represent,” said Phil Schneider, NACDS Foundation president. The deadline for all applications is Oct. 19.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?